SynDermix is a Swiss clinical-stage biotechnology company specialising in the development of leading-edge biopharmaceuticals and medical devices in areas of high unmet medical need.
Our pipeline is powered by 3 novel technologies: plant lectins, nitric oxide and vibration therapies.
We are working to develop ground-breaking therapies in the therapeutic areas of cancer supportive care, ENT, dermatology and gastroenterology.
Our technologies provide platforms for sustained innovation to address multiple health indications while simultaneously driving a wellcare pipeline.
SynDermix is funded by private investors and is preparing to list in the SIX Swiss Stock Exchange in 2019.